{"product_id":"retatrutide-20mg-10mg-5mg","title":"GODZILLA - (60mg,30mg, 20mg, 10mg, 5mg)","description":"\u003cp\u003e\u003cstrong\u003ePRODUCT DESCRIPTION\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePeptide Name: LY3437943\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eRESEARCHED AREAS AND BENEFITS\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\t\u003cli\u003e\t\u003cp\u003e\u003cstrong\u003eTriple receptor agonism synergy\u003c\/strong\u003e\u003c\/p\u003e\t\u003c\/li\u003e\t\u003cli\u003e\t\u003cp\u003e\u003cstrong\u003eUnprecedented weight reduction efficacy\u003c\/strong\u003e\u003c\/p\u003e\t\u003c\/li\u003e\t\u003cli\u003e\t\u003cp\u003e\u003cstrong\u003eHepatic steatosis resolution focus\u003c\/strong\u003e\u003c\/p\u003e\t\u003c\/li\u003e\t\u003cli\u003e\t\u003cp\u003e\u003cstrong\u003eGlycemic control insulin sensitivity\u003c\/strong\u003e\u003c\/p\u003e\t\u003c\/li\u003e\t\u003cli\u003e\t\u003cp\u003e\u003cstrong\u003eEnergy expenditure metabolic increase\u003c\/strong\u003e\u003c\/p\u003e\t\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003eChemical Name: L-Serinamide, L-tyrosyl-2-methylalanyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-L-leucyl-L-alpha-aspartyl-L-lysyl-N6-[N-(19-carboxy-1-oxononadecyl)-L-gamma-glutamyl-2-[2-(2-aminoethoxy)ethoxy]acetyl]-L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl\u003c\/p\u003e\u003cp\u003eCAS Number: 2381089-83-2\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDESCRIPTION \u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eRT is an investigational, first-in-class \"triple G\" agonist that targets three essential nutrient-stimulated hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG). By integrating these three pathways into a single peptide backbone, RT aims to achieve metabolic outcomes that exceed those of dual-agonist therapies like TZ. The addition of glucagon receptor activity is particularly significant, as it is researched for its ability to increase energy expenditure and fat oxidation directly in the liver, while the GLP-1 and GIP components manage appetite and glucose-dependent insulin secretion.\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cul\u003e\t\u003cli\u003e\t\u003cp\u003eWeight Management: Phase 3 clinical trials (2025-2026) have shown mean weight reductions exceeding 24% over 48 weeks, approaching the efficacy typically seen with bariatric surgery.\u003c\/p\u003e\t\u003c\/li\u003e\t\u003cli\u003e\t\u003cp\u003eMetabolic Health: Studies demonstrate significant improvements in HbA1c levels, with many participants achieving normoglycemia (A1C \u0026lt; 5.7%) during the trial period.\u003c\/p\u003e\t\u003c\/li\u003e\t\u003cli\u003e\t\u003cp\u003eLiver Fat Reduction: Research indicates a potent effect on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), with up to 90% of subjects in subset studies achieving normalization of liver fat.\u003c\/p\u003e\t\u003c\/li\u003e\t\u003cli\u003e\t\u003cp\u003eCardiovascular Markers: Data suggests secondary benefits in reducing systolic blood pressure and improving lipid profiles, specifically triglycerides and non-HDL cholesterol.\u003c\/p\u003e\t\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003e\u003cu\u003e\u003cstrong\u003eKIT INCLUDES:\u003c\/strong\u003e\u003c\/u\u003e\u003c\/p\u003e\u003cp\u003e1x Peptide Vial\u003c\/p\u003e\u003cp\u003e1x 10ml BAC Water\u003c\/p\u003e\u003cp\u003e1x Reconstitution Kit\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eREGULATORY NOTICES\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eSAHPRA DISCLAIMER This product has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA). It is not intended to diagnose, treat, cure, or prevent any disease.\u003c\/p\u003e\u003cp\u003eRESEARCH USE ONLY \u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSCIENTIFIC STUDIES\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\t\u003cli\u003e\t\u003cp\u003eTriple-Hormone-Receptor Agonist RT for Obesity: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\u003c\/p\u003e\t\u003c\/li\u003e\t\u003cli\u003e\t\u003cp\u003eRT (LY3437943), a novel GIP, GLP-1, and glucagon receptor agonist: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11486854\/\u003c\/p\u003e\t\u003c\/li\u003e\t\u003cli\u003e\t\u003cp\u003eLilly's Triple Agonist RT Phase 3 Diabetes Results (March 2026): https:\/\/investor.lilly.com\/news-releases\/\u003c\/p\u003e\t\u003c\/li\u003e\t\u003cli\u003e\t\u003cp\u003eEfficacy and safety of rT in obesity treatment - A Systematic Review: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12190491\/\u003c\/p\u003e\t\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIOLOABS PEPTIDES","offers":[{"title":"5","offer_id":49790787453170,"sku":null,"price":998.0,"currency_code":"ZAR","in_stock":true},{"title":"10","offer_id":49790787354866,"sku":null,"price":1168.0,"currency_code":"ZAR","in_stock":true},{"title":"20","offer_id":49790787420402,"sku":null,"price":1548.0,"currency_code":"ZAR","in_stock":true},{"title":"30","offer_id":49790787322098,"sku":null,"price":1948.0,"currency_code":"ZAR","in_stock":true},{"title":"60","offer_id":49790787387634,"sku":null,"price":3498.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0826\/5410\/1746\/files\/e97d91_334317333723423e9be74b3c3934ae14_mv2.jpg?v=1783750420","url":"https:\/\/biolabsresearch.co.za\/products\/retatrutide-20mg-10mg-5mg","provider":"BIOLABS PEPTIDES SOUTH AFRICA","version":"1.0","type":"link"}